Clinico-Hematological Findings for Classical Hodgkin's Lymphoma: an Institutional Experience

  • Sultan, Sadia (Department of Hematology & Blood bank, Liaquat National Hospital and Medical College) ;
  • Irfan, Syed Mohammed (Department of Hematology & Blood bank, Liaquat National Hospital and Medical College) ;
  • Parveen, Saira (Department of Hematology & Blood bank, Liaquat National Hospital and Medical College) ;
  • Ali, Saif (Liaquat National Medical College)
  • Published : 2016.08.01


Background: Classical Hodgkin's lymphoma (cHL) is a B-cell lymphoid neoplasm characterized by a distinctive biological behavior with potentially curable disease characteristics. It is an uncommon hematological malignancy which primarily affects younger individuals. The rationale of this study was to determine its clinico-hematological profile along with stage stratification in Pakistani patients. Materials and Methods: In this descriptive study, adult patients with Hodgkin's lymphoma were enrolled from January 2010 to December 2014. Results: Sixty two histopathologically confirmed cases of cHL were identified. There were 42 males and 20 females, with a male to female ratio of 2: 1. The mean age was $29.7{\pm}13.8$ years with the median age of 30 years. B symptoms were present in 72.5% of patients. Histopathologically, the mixed cellularity type constituted 62.9% of cases, followed by nodular sclerosis in 25.8%, lymphocyte predominant in 9.6% and lymphocyte depleted in 1.6%. Stages I and II were present in 43.5% of patients at disease presentation, with 56.4% in stages III and IV. Conclusions: Our analysis shows that clinico-pathological features of Hodgkin's lymphoma in Pakistan are comparable to published data. Mixed cellularity is the commonest histological variant and advanced stage at presentation are common findings in our patients.


  1. Ansell SM (2015). Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc, 90, 1574-83.
  2. Butt F, Akhtar R, Rahmani T, et al (2002). Bone marrow involvement in lymphoma: Incidence and co-relation with age and sex. Biomedica, 18 , 53-7.
  3. Fatima S, Ahmed R, Ahmed A (2011). Hodgkin lymphoma in Pakistan: an analysis of subtypes and their correlation with Epstein Barr virus. Asian Pac J Cancer Prev, 12, 1385-8.
  4. Ganesan P, Kumar L, Raina V (2011). Hodgkin's lymphomalong- term outcome: an experience from a tertiary care cancer center in North India. Ann Hematol, 90, 1153-60.
  5. Gad Allah H, El-Azzazi MO, Elafifi AM, et al (2014). Treatment outcome in Egyptian lymphoma patients, 2-year results, single-center experience. Egypt J Haematol, 39, 209-16.
  6. Grover NS, Park SI (2015). Novel targeted agents in hodgkin and non-Hodgkin lymphoma therapy. Pharmaceuticals, 8, 607-36.
  7. Gutensohn N, Cole P (1981). Childhood social environment and Hodgkin's disease. N EngL J Med, 304, 135-40.
  8. Hamid A, Hamid Am, Jabbar N, et al (2010). Significance of bone marrow biopsy in staging of Hodgkin's lymphoma. Ann King Edward Med University, 16, 12-16.
  9. Hodgkin (1832). On some morbid appearances of the absorbent glands and spleen. Med Chir Trans, 17, 68-114.
  10. Jalali A, Ha FJ, Chong G, et al (2016). Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era. Ann Hematol, [Epub ahead of print]
  11. Khan G, Norton AJ, Slavin G, (1993). Epstein Barr virus in Hodgkin's disease: Relation to age and subtype. Cancer, 71, 3124-9.<3124::AID-CNCR2820711038>3.0.CO;2-J
  12. Koren J, Trneny M (2015). Hodgkin's lymphoma - the treatment approaches development and current trends. Klin Onkol, 28, 387-94.
  13. Li X, Yang SE, Guo YQ, et al (2012). Clinical significance of quantitative analysis of plasma epstein- barr virus DNA in patients of Xinjiang Uygur nationality with Hodgkin's Lymphoma. Asian Pac J Cancer Prev, 13, 6379-84.
  14. Lone A, Naeem S (2011). Frequency and pattern of bone marrow infiltration in Hodgkin's Lymphoma. Biomedica, 27, 132-5.
  15. MacFarlane GL, Evstifeeva T, Boyle P, et al (1995). International patterns in the occurrence of Hodgkin’s disease in children and young adult males. Int J Cancer, 61, 165-9.
  16. Matteo ED, Baron AV, Chabay P, et al (2003). Comparison of Epstein Barr virus presence in Hodgkin’s lymphoma in pediatric versus adult Argentine patients. Arch Pathol Lab Med, 127, 1325-9.
  17. Maddi RN, Linga VG, Iyer KK, et al (2015). Clinical profile and outcome of adult Hodgkin lymphoma: Experience from a tertiary care institution. Indian J Med Paediatr Oncol, 36, 255-60.
  18. Nagi AH, Al-Menawy LA, Samiullah, et al (2008). A comparison of histological appearances of Hodgkin’s disease in Pakistani and Saudi patients. J Ayub Med Coll Abbottabad, 20, 66-9.
  19. Roshandel G, Semnani S, Aarabi M, et al (2011). Lymphomas in Golestan province of Iran: results of a population-based cancer registry. Asian Pac J Cancer Prev, 12, 219-22.
  20. Sader-Ghorra C, Rassy M, Naderi S, et al (2014).Type distribution of lymphomas in Lebanon: five-year single institution experience. Asian Pac J Cancer Prev, 15, 5825-8.
  21. Siddiqui N, Ayub B, Badar F, et al (2006). Hodgkin's lymphoma in Pakistan: a clinico-epidemiological study of 658 cases at a cancer center in Lahore. Asian Pac J Cancer Prev, 7, 651-5.
  22. Swerdlow SH, Campo E, Harris NL, et al (2008). WHO classification of tumors: pathology and genetics of tumors of haematopoietic and lymphoid Tissues. Lyon: IARC Press. pp. 321-34.
  23. Tang Y, Sun LG, Liu CS, et al (2013). Clinical analysis of stages of HBV infection in 100 cases of lymphoma. Asian Pac J Cancer Prev, 14, 959-62.
  24. Waravita TS, Wijetunge TS, Ratnatunga NV (2015). Pattern of lymphoma subtypes in a cohort of Sri Lankan patients. Ceylon Med J, 60, 13-7.
  25. Yung L, Linch D (2003). Hodgkin's lymphoma. Lancet, 361, 943-51.